ABIONYX Pharma has successfully secured EUR 33 million in financing through a fully subscribed capital increase and an initial bond drawdown. The company raised EUR 18.7 million via a rights issue and EUR 10 million from the first tranche of a bond financing facility provided by Fenja Capital. These funds are earmarked to fully finance the Phase 2b clinical trial in sepsis and the Marketing Authorization Application (MAA) for LCAT Deficiency, extending the company's cash runway into Q4 2028.

The rights issue, launched on May 27, 2026, resulted in the issuance of 7,056,416 new shares at a subscription price of EUR 2.65 per share. Existing shareholders subscribed for approximately 40% of the capital increase through the exercise of their subscription rights and fulfillment of guarantee commitments. Settlement and delivery of the new shares are expected on June 22, 2026, with admission to trading on Euronext Paris scheduled for the same date.

Rights Issue Allocation

Underwriting commitments were partially called to cover unsubscribed shares, totaling 4,888,546 new shares for EUR 12,954,646.90. The final gross amount of the rights issue reached EUR 18.7 million. Following the issuance, the company's share capital will consist of 42,568,071 shares.

Bonds Financing and Warrants

Fenja Capital provided the first tranche of EUR 10 million in non-convertible bonds, with issuance expected on June 25, 2026. A second tranche of EUR 4 million may be drawn in Q4 2026, subject to market capitalization and liquidity conditions. The bonds carry an interest rate of three-month EURIBOR plus 3.00% per annum, with a floor of 2.00%, and mature on May 26, 2028, extendable to November 26, 2028.

As part of the transaction, 2,240,424 warrants were issued to Fenja Capital, exercisable over five years at an initial price of EUR 3.71 per share. The warrants represent a potential dilution of 5.00% based on shares outstanding immediately after the transaction.

Use of Proceeds

The net proceeds from the transaction, estimated at approximately EUR 25.2 million, will be allocated to specific development milestones. EUR 10 million is designated for the Phase 2b sepsis trial, with study initiation planned for 2026 and topline data expected by the end of the first half of 2028. EUR 9 million will advance the LCAT Deficiency program toward an MAA submission to the EMA in early 2028. The remaining funds will support general corporate purposes and extend the cash runway into Q4 2028.

ABIONYX Pharma will hold its Combined Annual General Meeting on June 30, 2026, at 4:00 p.m. at its registered office located at 33-43 Av. Georges Pompidou, 31130 Balma, France. The biopharmaceutical company, focused on developing therapies for sepsis and critical care, has made the preparatory documents available on its website under the "Investors" section.

Shareholders can cast their votes by attending the meeting in person or by mail using a mail-in ballot or by granting proxy to the Chair of the Meeting. The voting procedures are detailed in the prior notice published in the BALO on May 22, 2026.

For those unable to attend, ABIONYX Pharma will provide a live broadcast of the meeting via a specific link on its website. However, the broadcast will not allow for remote voting or questions. A replay of the meeting will be made available on the company's website following the event.

Meeting Details

Voting Options

• Attend in person
• Vote by mail (mail-in ballot)
• Grant proxy to the Chair of the Meeting

ABIONYX Pharma specializes in innovative therapies based on a proprietary apoA-I technology platform, targeting immune-inflammatory dysregulation in sepsis and other severe diseases.